Vaccibody $VACC leaping to ATH after releasing #Covid19 Data
Vaccibody reports promising preclinical data with a second-generation COVID-19 vaccine and announces its infectious disease strategy
● Vaccibody demonstrates promising pre-clinical data with its second-generation COVID-19 vaccine candidate, VB10.COV2
● VB10.COV2 induces rapid, strong and long-lasting neutralizing antibodies and multifunctional, dominant CD8+ T cell and Th1 CD4+ T cell responses in mice after a single dose
● Vaccibody will present the pre-clinical data and its broader infectious disease strategy during a webcast on Friday December 11 at 10 am CET
● Vaccibody demonstrates promising pre-clinical data with its second-generation COVID-19 vaccine candidate, VB10.COV2
● VB10.COV2 induces rapid, strong and long-lasting neutralizing antibodies and multifunctional, dominant CD8+ T cell and Th1 CD4+ T cell responses in mice after a single dose
● Vaccibody will present the pre-clinical data and its broader infectious disease strategy during a webcast on Friday December 11 at 10 am CET
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.